Eye (London, England) · 2026
Incidence and characteristics of newly formed polypoidal lesions in polypoidal choroidal vasculopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Jaehwan, Kim Dongkyu, Kim Kiyoung, Yu Seung-Young
Аннотация
OBJECTIVES: To evaluate the incidence of newly formed polypoidal lesions (PLs) and associated neovascular lesion changes in eyes with polypoidal choroidal vasculopathy (PCV) using optical coherence tomography angiography (OCTA).
METHODS: The medical records of patients diagnosed with PCV who were treated with intravitreal anti-vascular endothelial growth factor therapy and followed up for at least 3 years were retrospectively reviewed. Patients were classified into a new PL group or no new PL group based on the development of new PLs on OCTA during the follow-up period. The primary outcome measures included the incidence of new PLs and changes in morphological characteristics (area and circularity) of the neovascular lesions.
RESULTS: The final analysis included 45 eyes from 45 patients. New PLs were observed in 15 (33.3%) eyes. The new PL group demonstrated a significantly greater increase in neovascular lesion area compared with the no new PL group (1.63 ± 0.54 mm² vs. 0.19 ± 0.54 mm²; P = 0.041). Furthermore, the new PL group exhibited a significant decline in neovascular lesion circularity compared with the no new PL group (-0.052 ± 0.040 vs. 0.029 ± 0.030; P = 0.004). Most new PLs (80%) were classified as de novo, defined as those developing in a location where no neovascular lesions were present at the previous visit.
CONCLUSION: New PL formation frequently occurs in patients with PCV undergoing a treat-and-extend protocol. Expansion of the neovascular area and worsening of circularity have been identified as key precursors of new PL development.
METHODS: The medical records of patients diagnosed with PCV who were treated with intravitreal anti-vascular endothelial growth factor therapy and followed up for at least 3 years were retrospectively reviewed. Patients were classified into a new PL group or no new PL group based on the development of new PLs on OCTA during the follow-up period. The primary outcome measures included the incidence of new PLs and changes in morphological characteristics (area and circularity) of the neovascular lesions.
RESULTS: The final analysis included 45 eyes from 45 patients. New PLs were observed in 15 (33.3%) eyes. The new PL group demonstrated a significantly greater increase in neovascular lesion area compared with the no new PL group (1.63 ± 0.54 mm² vs. 0.19 ± 0.54 mm²; P = 0.041). Furthermore, the new PL group exhibited a significant decline in neovascular lesion circularity compared with the no new PL group (-0.052 ± 0.040 vs. 0.029 ± 0.030; P = 0.004). Most new PLs (80%) were classified as de novo, defined as those developing in a location where no neovascular lesions were present at the previous visit.
CONCLUSION: New PL formation frequently occurs in patients with PCV undergoing a treat-and-extend protocol. Expansion of the neovascular area and worsening of circularity have been identified as key precursors of new PL development.